DLP30 mg

DLP 30 mg is a proton pump inhibitor (PPI) prescribed to reduce excessive stomach acid and to heal acid-related damage to the esophagus. It is clinically indicated for the following conditions:

• Healing of Erosive Esophagitis (EE): Used to heal all grades of erosive esophagitis caused by acid reflux, for a treatment course of up to 8 weeks.
• Maintenance of Healed Erosive Esophagitis: Used to maintain the healing of erosive esophagitis and to provide continued relief from heartburn for up to 6 months.
• Symptomatic Non-Erosive GERD: Used to treat heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for a period of 4 weeks.

DLP 30 mg helps relieve persistent heartburn, acid regurgitation, and discomfort linked to gastric acid, allowing damaged esophageal tissue to heal over time.

DLP 30 mg belongs to the therapeutic class of Proton Pump Inhibitors (PPIs), a group of medicines that reduce stomach acid production and are widely used to treat acid-related gastrointestinal disorders.

DLP 30 mg is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specifically inhibiting the (H+/K+)-ATPase enzyme system, commonly known as the "proton pump," located in the gastric parietal cells. By targeting this enzyme, DLP 30 mg blocks the final step of acid production, thereby reducing both basal and stimulated stomach acid output.

DLP 30 mg is the R-enantiomer of lansoprazole, which is itself a racemic mixture of the R- and S-enantiomers. This enantiomer-specific composition contributes to its distinct pharmacokinetic profile.

A key feature of DLP 30 mg is its Dual Delayed Release (DDR) formulation. Each capsule contains two types of enteric-coated granules that dissolve at different pH levels, producing a plasma concentration-time profile with two separate peaks. The first peak occurs approximately 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. This dual-release mechanism extends the duration of acid suppression compared with conventional single-release PPIs.

Following oral administration, the mean maximum plasma concentration (Cmax) and area under the curve (AUC) increase in an approximately dose-proportional manner. DLP 30 mg is extensively metabolized in the liver and is primarily excreted through the urine.

Interaction with other medicines: DLP 30 mg may interact with certain drugs, potentially altering their effectiveness or increasing the risk of side effects. Caution is advised when it is used alongside the following:

• Atazanavir: Reduced acid levels may lower the absorption and effectiveness of this antiretroviral medicine.
• Warfarin: Co-administration may affect blood clotting; monitoring may be required.
• Tacrolimus: Blood levels of tacrolimus may increase.
• Clopidogrel: The activation of this antiplatelet drug may be affected.
• Methotrexate: Concomitant use may raise methotrexate levels, particularly at high doses.

Interaction with food & others: No specific data available. Inform your physician about all medicines, supplements, and herbal products you are taking before starting DLP 30 mg.

Like all medicines, DLP 30 mg may cause side effects, although not everyone experiences them. Most side effects are mild and gastrointestinal in nature.

Common side effects include:

• Diarrhea
• Abdominal pain
• Nausea
• Vomiting
• Flatulence (gas)

If any side effect becomes severe or persistent, or if you experience an allergic reaction, seek medical advice promptly.

Pregnancy Category B. There are no adequate and well-controlled studies of DLP 30 mg in pregnant women. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under the guidance of a physician.

Lactation: There are no adequate and well-controlled studies of DLP 30 mg in breastfeeding mothers. Because it is not established whether the drug passes into human milk, caution should be exercised and a physician consulted before use during lactation.

Before and during treatment with DLP 30 mg, the following precautions should be considered:

• Gastric Malignancy: Symptomatic relief does not rule out the presence of gastric cancer. If symptoms persist despite treatment, further investigation may be needed.
• Clostridium difficile–Associated Diarrhea: PPI therapy may increase the risk of this infection. Persistent diarrhea that does not improve should be evaluated.
• Bone Fracture: Long-term, high-dose PPI use may be associated with an increased risk of fractures of the hip, wrist, or spine.
• Hypomagnesemia: Prolonged use may lead to low blood magnesium levels, which may require monitoring.
• Concomitant use with Methotrexate: Caution is advised, as this combination may increase methotrexate levels, especially with high-dose methotrexate therapy.

There have been no reports of a significant overdose of DLP 30 mg. In clinical experience, multiple doses of 120 mg and a single dose of 300 mg did not result in death or other severe adverse effects. In the event of a suspected overdose, treatment should be symptomatic and supportive, and immediate medical attention should be sought.

Store DLP 30 mg below 30°C in a cool, dry place, protected from direct light and moisture. Keep the medicine in its original packaging and out of the reach of children. Do not use after the expiry date printed on the packaging.

• Children & Adolescents: The safety and effectiveness of DLP 30 mg in patients below 12 years of age have not been established.
• Geriatric Use: No dose adjustment is necessary for elderly patients.
• Renal Impairment: No dose adjustment is required for patients with impaired kidney function.
• Hepatic Impairment: No dose adjustment is needed for patients with mild liver impairment. For patients with moderate hepatic impairment, a maximum daily dose of 30 mg should be considered. Use in severe hepatic impairment should be under close medical supervision.

Proton Pump Inhibitor

DLP 30 mg delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, DLP 30 mg blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). DLP 30 mg is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in DLP 30 mg, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of DLP 30 mg increased approximately dose proportionally. DLP 30 mg is extensively metabolized in the liver and excreated by urine.

Pregnancy Category B. There is no adequate and well-controlled studies with DLP 30 mg in pregnant women. There is no adequate and well-controlled studies with DLP 30 mg in Lactating mother.

Use in children & adolescents: Safety and effectiveness of DLP 30 mg in patients below 12 years age have not been established.Geriatric use: No dose adjustment is necessary for elderly patients.Renal impairment: No dose adjustment of DLP 30 mg is necessary for patients with renalimpairment.Hepatic impairment: No dose adjustment for DLP 30 mg is necessary for patients with mild hepatic impairment. A maximum daily dose of DLP 30 mg 30 mg should be considered for patients with moderate hepatic impairment.